TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39007997
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg caffeine
Study: 35238144
Drug: Topical finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical finasteride
Study: 34634163
Drug: Oral finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral finasteride
Study: 33926704
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of antithrombin III (n = 64)
Study: 33926704
Drug: Non-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-administration of antithrombin III (n = 77)
Study: 33634665
Drug: Treatment-While-Incarcerated (TWI)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-While-Incarcerated (TWI)
Study: 32050695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group performing daily soccer routine (CG)
Study: 36107530
Drug: Bevel facing
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevel facing left (Group L)
Study: 33261542
Drug: Fructose (75g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (75g in 200mL solution)
Study: 32316801
Drug: Leucovorin rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin rescue at 24 hours after HDMTX infusion
Study: 32316801
Drug: Leucovorin rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin rescue at 18 hours after HDMTX infusion
Study: 32882429
Drug: MG probing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG probing plus post‐procedural topical sulfacetamide/prednisolone ointment (Blephamide®)
Study: 33878763
Drug: Algorithm B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm B (high-dose algorithm considering additional insulin for fat protein units)
Study: 32240527
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg every 2 weeks)
Study: 34737296
Drug: Peg-IFN-α-2b therapy
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-IFN-α-2b therapy
Study: 38085312
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus insulin
Study: 34792531
Drug: Chemoradiotherapy (CRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT) before chemotherapy
Study: 33129376
Drug: Venetoclax (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (800 mg per day orally) plus bortezomib (1·3 mg/m2) and dexamethasone (20 mg orally)
Study: 33129376
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus bortezomib (1·3 mg/m2) and dexamethasone (20 mg orally)
Study: 33438529
Drug: 3DIZI-guided injections
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3DIZI-guided injections
Study: 33438529
Drug: Standard ultrasound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ultrasound-guided injections
Study: 32155200
Drug: Combined antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiretroviral therapy (cART)
Study: 34755389
Drug: 500 ml of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of semi‐skimmed milk containing approximately 600 mg of calcium with 200 µg of cholecalciferol
Study: 35246030
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus dose, followed by a 2 mg/kg/h continuous infusion)
Study: 39320582
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg BID
Study: 39320582
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID
Study: 32362168
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice combined with oral nutritional supplements
Study: 36263240
Drug: Nonsurgical spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical spinal decompression therapy (NSDT)
Study: 35487526
Drug: 50.4 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.4 Gy to the primary tumour and surrounding mesorectum with concurrent chemotherapy (capecitabine, 5-fluorouracil/leucovorin or omitted)
Study: 34965712
Drug: Rehabilitation complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation complex including therapeutic exercises, mechanotherapy, electrical stimulation, gravitational therapy, and antiresorptive therapy (10 procedures)
Study: 39256427
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES)
Study: 32511143
Drug: Multimodal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal group received infiltration with 0.5% bupivacaine 92.5 mg (18.5 mL), ketorolac 30 mg (1 mL), morphine 5 mg (0.5 mL), and epinephrine 0.5 mg (0.5 mL)
Study: 34351426
Drug: β‐blocker therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐blocker therapy (agent and dose according to treating physician)
Study: 33829225
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of subsidies on healthy products and taxes on unhealthy products in the nudging and price salience condition
Study: 36708956
Drug: Agomelatine 25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25-50 mg/day
Study: 34996516
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy
Study: 36495775
Drug: Protective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilation (PV): tidal volume = 6 ml/kg of predicted body weight, PEEP = 10 cmH2O, recruitment maneuvers
Study: 33553968
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after therapy
Study: 34958394
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of carbide burs and Sof-Lex discs
Study: 36659832
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (not explicitly mentioned in the abstract)
Study: 33938307
Drug: PGX-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGX-guided treatment
Study: 32941700
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blocker
Study: 32208439
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker
Study: 35576956
Drug: Adebrelimab plus
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab plus chemotherapy (carboplatin and etoposide)
Study: 35576956
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (carboplatin and etoposide)
Study: 39671272
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy
Study: 33472641
Drug: Hypertonic sodium
Normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic sodium infusion
Study: 33010371
Drug: i-gel supraglottic
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel supraglottic airway device (SGA)
Study: 35731889
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of suvorexant
Study: 32207140
Drug: Medical expulsive
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical expulsive therapy (MET) with 0.4 mg daily tamsulosin
Study: 32196621
Drug: Myo-inositol (MI)
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol (MI) treatment
Study: 33753043
Drug: dd‐MVAC (dose‐dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: dd‐MVAC (dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Study: 36054143
Drug: Moxifloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (800 mg/day for 4 days)
Study: 35578103
Drug: Participatory art-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participatory art-based activity (2 hours weekly for 12 weeks)
Study: 34753480
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg orally once daily
Study: 34258380
Drug: Dual antithrombotic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antithrombotic therapy (DAT) with apixaban plus clopidogrel
Study: 34258380
Drug: Triple antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombotic therapy (TAT) with vitamin-K-antagonist (VKA) plus clopidogrel and acetylsalicylic acid
Study: 32670199
Drug: Jinlida granules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinlida granules, 9 g/time, three times daily for 2-4 years, in addition to lifestyle intervention
Study: 32670199
Drug: Placebo, orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, 9 g/time, three times daily for 2-4 years, in addition to lifestyle intervention
Study: 34905220
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of primaquine (0.0625 to 0.5 mg base/kg)
Study: 35504639
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care consisting of analgesia, and regular input from the medical and therapy team.
Study: 33871648
Drug: Capsaicin 179
Normalized name: Capsaicin 179 mg cutaneous patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 179 mg cutaneous patch
Study: 39339810
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment
Study: 38537483
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT)
Study: 32115517
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy
Study: 32817142
Drug: 99mTc-ADAPT6 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-ADAPT6 (500 μg)
Study: 32817142
Drug: 99mTc-ADAPT6 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-ADAPT6 (250 μg)
Study: 32817142
Drug: 99mTc-ADAPT6 (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-ADAPT6 (1,000 μg)
Study: 36217555
Drug: Cold Atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Atmospheric Plasma (CAP) treatment biweekly for five sessions
Study: 33495378
Drug: Genetic predisposition
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic predisposition to insulin resistance
Study: 34044738
Drug: Breathing exercise
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing exercise program performed twice per day for one month
Study: 35078923
Drug: Induction chemoimmunotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy (RIT)
Study: 32776464
Drug: L-citrulline (CIT)
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-citrulline (CIT) supplementation (6g/day)
Study: 34074559
Drug: Dual immunotherapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual immunotherapy of ipilimumab and nivolumab
Study: 35578303
Drug: Prolonged requirement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged requirement for insulin (PRI) on Day 5
Study: 35578303
Drug: No prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prolonged requirement for insulin (non-PRI)
Study: 32679238
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment plus usual care
Study: 33433786
Drug: Primary IORT
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary IORT with compliance to endocrine therapy
Study: 35369700
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of standard therapy (control group)
Study: 35102424
Drug: THC (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (both doses)
Study: 39160110
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy
Study: 34910143
Drug: DMPA-IM vs
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA-IM vs LNG implant
Study: 33336360
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral misoprostol solution (OMS)
Study: 32935261
Drug: Parent-Child Interaction
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Child Interaction Therapy focused on Emotional Development (PCIT-ED), n = 114
Study: 34308314
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2400 mg/day for 12 weeks
Study: 35272971
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery (Cambridge hybrid closed-loop algorithm)
Study: 35272971
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with insulin pump therapy (control group)
Study: 35272971
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery (FlorenceM configuration)
Study: 35272971
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery (CamAPS FX configuration)
Study: 33082016
Drug: LSD 5
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 5 mcg
Study: 33082016
Drug: LSD 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 10 mcg
Study: 32856251
Drug: Zinc threonine
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc threonine chelate (80 and 120 mg zinc per kg feed)
Study: 32856251
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no zinc supplementation)
Study: 32856251
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (40, 80, and 120 mg zinc per kg feed)
Study: 32856251
Drug: Commercial chelate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial chelate (Bioplex Zn®) (40 mg zinc per kg feed)
Study: 33930380
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally followed by misoprostol 800 mcg vaginally 24 hours later
Study: 33513929
Drug: 548 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 548 mg/day of polyphenols and 2 g/day of L-citrulline for 6 weeks
Study: 32663102
Drug: Indacaterol 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 110 µg/glycopyrronium 50 µg once daily (OD)
Study: 32663102
Drug: Tiotropium 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 50 µg OD
Study: 35595661
Drug: TAK-214 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-214 vaccine (15/15, 15/50, 50/50, or 50/150 μg of GI.1/GII.4c genotype VLPs with 0.5 mg Al(OH)3)
Study: 39449089
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control
Study: 33476659
Drug: Mifepristone followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone followed by misoprostol (200 mg oral mifepristone followed by 800 mcg vaginal misoprostol)
Study: 37428480
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg)
Study: 33687525
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (JAK inhibitor)
Study: 35725922
Drug: Licogliflozin 150
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 150 mg
Study: 35725922
Drug: Licogliflozin 30
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 30 mg
Study: 33951362
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg intravenous)
Study: 33593789
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including nutrition optimization, parenting program with cognitive-behavioral therapy, lifestyle behavior change, and reduction of environmental pollution.
Study: 32065939
Drug: COPE (integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE (integrated treatment using prolonged exposure)
Study: 32065939
Drug: Seeking Safety
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seeking Safety (integrated therapy using cognitive behavioral, interpersonal techniques and case management)
Study: 36477031
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg)
Study: 35074903
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg) + Nivolumab (1 mg/kg)
Study: 36262221
Drug: Adapted person-centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted person-centered prescription (PCP) model
Study: 35221687
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg
Study: 35221687
Drug: Vortioxetine 20
Normalized name: vortioxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 20 mg
Study: 33879733
Drug: rhBNP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBNP group (basic treatment combined with rhBNP)
Study: 33879733
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment group (treated with an angiotensin‐converting enzyme inhibitor, β receptor blocker, and corticosteroid antagonist)
Study: 37815957
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment
Study: 37660042
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT)
Study: 35099263
Drug: Mentalization-Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-Based Therapy Intensive Outpatient (MBT-IOP)
Study: 35099263
Drug: Mentalization-Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-Based Therapy Day Hospital (MBT-DH)
Study: 34430672
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy (CPT)
Study: 32259774
Drug: Alpha lipoic
Normalized name: Alpha Lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha lipoic acid (ALA) 300 mg twice daily for 3 months
Study: 36416836
Drug: Ipilimumab or
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab or high-dose interferon α 2b (HDI)
Study: 33650299
Drug: Selenious yeast
Normalized name: Selenious Acid
DrugBank: Selenious acid (DB11127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenious yeast tablet (SYT) for 6 months
Study: 34562067
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single ascending dose)
Study: 35042007
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow aspirate concentrate (BMAC) augmentation
Study: 33793636
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume simethicone (1125 mg in 750 ml water)
Study: 33793636
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume simethicone (300 mg in 200 ml water)
Study: 32992151
Drug: Enhanced Treatment-As-Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment-As-Usual (ETAU)
Study: 32479135
Drug: DRM02, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRM02, a novel phosphodiesterase-4 inhibitor, applied topically in mouse models.
Study: 32479135
Drug: DRM02, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRM02, a novel phosphodiesterase-4 inhibitor, applied topically in a mouse model of psoriasis.
Study: 32479135
Drug: DRM02 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DRM02 treatment of cultured primary human and mouse epidermal keratinocytes.
Study: 35189669
Drug: Repeat colonoscopy
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat colonoscopy with adequate bowel preparation
Study: 38795110
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy
Study: 33305626
Drug: 50000 IU
Normalized name: Ergocalciferol 50000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50000 IU vitamin D weekly for 12–14 weeks
Study: 32843286
Drug: Vestronidase alfa,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestronidase alfa, rhGUS enzyme replacement therapy
Study: 32648260
Drug: CNS relapse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CNS relapse treatment (heterogeneous)
Study: 34864649
Drug: Timolol nasal
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol nasal spray (1 mg/d)